Blog & Resources Camargo Blog December 3rd, 2008

505(b)(2) Combination Meets Phase 3 Goals

Horizon Therapeutics announced yesterday that its “fixed-dose combination product containing ibuprofen and famotidine, demonstrated a statistically significant reduction in the incidence of non-steroidal anti-inflammatory drug (NSAID)-induced upper gastrointestinal (gastric and/or duodenal) ulcers in patients with mild-to-moderate pain when compared to ibuprofen alone.” Note that the drug development program contained two Phase 3 trials, one examining gastric ulcers only, the other examining gastric and/or duodenal ulcers.

There are a number of development programs trying to find solutions to NSAID-induced ulcers. NSAIDs are very effective pain reducing agents. People with osteoarthritis need to take NSAIDs for life. Yet NSAIDs are known to cause gastric ulcers. Products like Horizon’s attempt to change the acidic environment in the stomach, other products are being developed to modify the NSAID to avoid action in the stomach. These pro-drugs release the NSAID latter in the intestine or in the blood stream. None are totally effective since circulating NSAID can cause ulcers.

Get Our Expertise Working for You

To learn how you can benefit from our regulatory and strategic development expertise, view our solutions or contact us.

Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.

9825 Kenwood Road
Suite 203
Cincinnati OH, 45242
Durham Office
800 Taylor Street
Suite 101
Durham NC, 27701
Montreal Office
507 Place d'Armes
Suite 1101
Montreal, QC H2Y 2W8, Canada
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights